Myeloid differentiation factor-2/LY96, a new predictive biomarker of metastasis in prostate cancer: Clinical implications as a potential therapeutic target

Relapsed prostate cancer (CaP), usually treated with androgen deprivation therapy, acquires resistance to develop into lethal metastatic castration-resistant CaP. The cause of resistance remains elusive, and the lack of biomarkers predictive of castration-resistance emergence is a stumbling block in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrari, Marina, Wang, Li, Hoeppner, Luke, Hahm, Eunsil, Yu, Jindan, Kuzel, Timothy, MANSINI, ADRIAN
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275058/
https://www.ncbi.nlm.nih.gov/pubmed/37333086
http://dx.doi.org/10.21203/rs.3.rs-2968406/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275058/
https://www.ncbi.nlm.nih.gov/pubmed/37333086
http://dx.doi.org/10.21203/rs.3.rs-2968406/v1

Ejemplares similares